|
|
|
|
| LEADER |
03520nmm a2200361 u 4500 |
| 001 |
EB001345548 |
| 003 |
EBX01000000000000000899738 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
170203 ||| eng |
| 020 |
|
|
|a 9783319427690
|
| 100 |
1 |
|
|a Bolla, Michel
|e [editor]
|
| 245 |
0 |
0 |
|a Management of Prostate Cancer
|h Elektronische Ressource
|b A Multidisciplinary Approach
|c edited by Michel Bolla, Hendrik van Poppel
|
| 250 |
|
|
|a 2nd ed. 2017
|
| 260 |
|
|
|a Cham
|b Springer International Publishing
|c 2017, 2017
|
| 300 |
|
|
|a VIII, 422 p. 76 illus., 64 illus. in color
|b online resource
|
| 505 |
0 |
|
|a Epidemiology of prostate cancer in Europe -- Chemoprevention -- Individual and mass screening -- Anatomo-pathology -- Biology -- Genomics -- Radiologic investigations( multiparametric MRI, whole body MRI) -- Nuclear Medecine: follow-up (Choline PET-CT, Radium 223)and treatment of bone metastases -- Diagnosis, clinical work up, TNM classification Markers -- Active surveillance -- Open Radical Prostatectomy -- The robotic laparoscopic radical prostatectomy -- Brachytherapy (Low dose rate) -- Brachytherapy (High dose rate) -- IMRT, hypofractionated irradiation and stereotactic irradiation -- External irradiation + androgen suppression -- Post-operative irradiation: immediate or early delayed?- High Intensity Focused Ultrasound -- Cryotherapy -- Follow-up after radical treatments* and relapse -- First line hormonal manipulations -- Upfront chemotherapy at initiation of hormonal treatment for metastatic prostate cancer -- Bone-targeted therapies (Bisphosphonates, denosumab and Radium 223 -- Targeted therapies and vaccination -- How to interprete results -- Prostate EAU guidelines -- Better Patients perspective
|
| 653 |
|
|
|a Cancer research
|
| 653 |
|
|
|a Radiotherapy
|
| 653 |
|
|
|a Urology
|
| 653 |
|
|
|a Oncology
|
| 653 |
|
|
|a Epidemiology
|
| 653 |
|
|
|a Epidemiology
|
| 653 |
|
|
|a Oncology
|
| 653 |
|
|
|a Cancer Research
|
| 653 |
|
|
|a Radiotherapy
|
| 653 |
|
|
|a Urology
|
| 700 |
1 |
|
|a van Poppel, Hendrik
|e [editor]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b Springer
|a Springer eBooks 2005-
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-319-42769-0?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 616.994
|
| 520 |
|
|
|a This book, now in an extensively revised second edition, provides an exhaustive review of the state of the art in the management of prostate cancer, from screening to treatment, with emphasis on a multidisciplinary approach. The editors are very excited about the outstanding new or updated contributions from the different expert authors. The opening chapters address basic aspects including epidemiology, pathology, biology, genetics, and chemoprevention. The role of individual and mass screening is carefully appraised, and extensive attention is devoted to diagnosis and clinical work-up by means of recently implemented investigations such as multiparametric MRI and choline PET-CT. The use of active surveillance is examined in detail. Subsequent chapters discuss the different therapies that may be employed: open and minimally invasive, including robot-assisted, radical prostatectomy, the various forms of radiation treatment, high-intensity focused ultrasound, cryotherapy, hormonal manipulations, chemotherapy, targeted therapies, and immunotherapy. Up-to-date results from practice-changing phase III randomized clinical trials are included and special insights are provided into the interpretation of results and the patient’s perspective
|